EANS-Adhoc: SYGNIS Pharma AG
SYGNIS Pharma AG decides on increase in share
capital
20.07.2011 – 16:11
-------------------------------------------------------------------------------- ad-hoc disclosure pursuant to section 15 of the WpHG transmitted by euro adhoc with the aim of a Europe-wide distribution. The issuer is solely responsible for the content of this announcement. -------------------------------------------------------------------------------- 20.07.2011 Ad-hoc release SYGNIS Pharma AG decides on increase in share capital Heidelberg, 20 July 2011 - Today the Management Board of the Heidelberg-based SYGNIS Pharma AG (Frankfurt: LIOK; ISIN DE000A1E9B74; Prime Standard), with the approval of the Supervisory Board, decided to increase the equity capital from euro 13,752,881 to up to euro 16,988,853, by issuing up to 3,235,972 no-par value bearer shares from authorised capital. The new shares are to be offered to the shareholders at a subscription price of euro 2.00 per new share. The shareholders can subscribe to the new shares with dividend rights from 1 April 2010 in a 17:4 ratio within the subscription period which lasts from 26 July until 9 August 2011 (full days included). Moreover, as part of an additional purchase existing shareholders have the opportunity to subscribe for additional shares which have not been subscribed by other shareholders. In June 2011 dievini Hopp BioTech holding GmbH & Co. KG (dievini) has committed financial funds of euro 6 million on the basis of a loan agreement. Based on dievini´s commitment these funds shall be invested within this capital increase in receipt of new shares worth up to euro 6 million. Accordingly, the loan amount will be reduced by the amount which dievini will invest as part of this capital increase. An organized trade in subscription rights will not occur. The approval of the new shares for trading in the regulated market (Prime Standard) at the Frankfurt Stock Exchange is not expected before 17 August 2011. Further details of the capital increase will be provided in the subscription offer expected to be published in the electronic Federal Gazette (elektronischer Bundesanzeiger) on 25 August 2011. The capital increase is conducted by Landesbank Baden- Württemberg. The proceeds are to be used for financing SYGNIS´ existing operations, according to the present plans, at least until the end of 2012 and in particular for the completion of the current efficacy trial for AX200 for the treatment of acute stroke (AXIS 2) and the potential commercialization of this project. For further information please contact: |Dr. Franz-Werner Haas | |Senior VP Operations | |Tel: +49 (0) 6221-454 812 | |Email: franz-Werner.haas@sygnis.de | ### Disclaimer This publication is intended for information only and constitutes neither an offer to sell nor an invitation to buy securities. The shares in SYGNIS Pharma AG (the 'Shares') may not be offered or sold in the United States or to or for the account or benefit of 'U.S. persons' (as such term is defined in Regulation S under the U.S. Securities Act of 1933, as amended (the 'Securities Act')). No offer or sale of transferable securities is being made to the public. The shares are offered solely on the basis of subscription rights. This document is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) to investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order') or (iii) high net worth entities, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as 'relevant persons'). The Shares are only available to, and any invitation, offer or agreement to subscribe, purchase or otherwise acquire such securities will be engaged in only with, relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward- looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ### Further inquiry note: Michael Wolf Telefon: +49 (6221) 454 - 6 E-Mail: Michael.Wolf@sygnis.de end of announcement euro adhoc -------------------------------------------------------------------------------- issuer: SYGNIS Pharma AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1E9B74 indexes: CDAX, Prime All Share stockmarkets: regulated dealing/prime standard: Frankfurt, free trade: Berlin, Hamburg, Stuttgart, Düsseldorf, Hannover, München language: English